Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoidesInvivoscribe Marketing2021-02-11T21:43:52-08:00June 8th, 2020|Read more
Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation SequencingInvivoscribe Marketing2021-02-11T21:47:46-08:00May 19th, 2020|Read more
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentInvivoscribe Marketing2021-02-15T19:48:14-08:00May 6th, 2020|Read more
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple MyelomaInvivoscribe Marketing2021-02-11T21:50:38-08:00May 1st, 2020|Read more
Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV statusInvivoscribe Marketing2021-02-11T21:53:32-08:00April 1st, 2020|Read more
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55-08:00April 28th, 2017|Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02-08:00April 28th, 2017|Read more
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49-08:00March 28th, 2017|Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58-08:00February 28th, 2017|Read more
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04-08:00February 14th, 2017|Read more
The 48th Annual Meeting of the Molecular Biology Society of JapanDecember 3-5, 2025 Yokohama, Japan Attending Visit Conference Website